60 Degrees Pharmaceuticals (SXTP) Projected to Release Earnings on Wednesday

60 Degrees Pharmaceuticals (NASDAQ:SXTP) is expected to be posting its Q2 2026 results before the market opens on Wednesday, August 12th. Analysts expect the company to announce earnings of ($0.74) per share and revenue of $0.1850 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Friday, August 14, 2026 at 9:30 AM ET.

60 Degrees Pharmaceuticals (NASDAQ:SXTP) last posted its earnings results on Friday, May 15th. The company reported ($1.28) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.52). The business had revenue of $0.16 million for the quarter, compared to analysts’ expectations of $0.43 million. On average, analysts expect 60 Degrees Pharmaceuticals to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

60 Degrees Pharmaceuticals Trading Up 1.2%

SXTP opened at $1.25 on Wednesday. The business’s 50 day moving average is $1.52 and its 200-day moving average is $2.11. The stock has a market cap of $3.31 million, a PE ratio of -0.14 and a beta of 2.54. 60 Degrees Pharmaceuticals has a twelve month low of $1.05 and a twelve month high of $8.62.

Analyst Ratings Changes

Several research firms recently commented on SXTP. Wall Street Zen cut 60 Degrees Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Sunday, April 12th. Ascendiant Capital Markets decreased their price target on 60 Degrees Pharmaceuticals from $4.20 to $3.70 and set a “buy” rating for the company in a research note on Friday, May 22nd. HC Wainwright lowered 60 Degrees Pharmaceuticals from a “buy” rating to a “neutral” rating in a report on Wednesday, May 20th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of 60 Degrees Pharmaceuticals in a research note on Wednesday, June 24th. One research analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $13.85.

About 60 Degrees Pharmaceuticals

60 Degrees Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue.